Literature DB >> 2473660

Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison.

D J Bollinger1, M R Wick, L P Dehner, S E Mills, P E Swanson, R E Clarke.   

Abstract

In order to evaluate adjunctive histologic methods for separating mesothelioma (MM) and serous adenocarcinoma (SC), we studied 28 and 46 respective cases histochemically and immunohistochemically. Ten serous adenocarcinomas arose primarily in extraovarian sites within the abdomen. Diagnoses in each case were established retrospectively by a combination of electron microscopy and clinicopathologic correlation. A panel of antibodies to cytokeratin (CK), epithelial membrane antigen (EMA), B72.3, placental alkaline phosphatase (PLAP), S-100 protein, carcinoembryonic antigen (CEA), Leu M1, CA-125, and amylase (AM) was applied to paraffin sections of each case. Serous carcinoma was reactive for neutral mucins whereas mesothelioma was not; however, only 50% of adenocarcinoma cases stained in this manner. Peritoneal mesothelioma showed reactivity for CK (28 of 28 cases), EMA (24 of 28 cases), AM (five of 28 cases), CA-125 (four of 28 cases), and S-100 protein (three of 28 cases), but lacked B72.3, PLAP, and CEA. Three mesotheliomas expressed Leu M1, but in an extremely focal distribution. Serous carcinoma reacted for CK (46 of 46 cases), EMA (46 of 46 cases), CA-125 (42 of 46 cases), S-100 protein (40 of 46 cases), Leu M1 (34 of 46 cases; with diffuse staining), B72.3 (33 of 46 cases), PLAP (29 of 46 cases), AM (15 of 46 cases), and CEA (six of 46 cases). Two profiles (S-100 + B72.3; S-100 + PLAP) were seen in 41 of 46 serous adenocarcinoma cases but were absent in all mesotheliomas. Hence, these combinations of determinants are effective in separating such neoplasms diagnostically. Moreover, diffuse reactivity for Leu M1, B72.3, PLAP, or CEA in papillary peritoneal neoplasms appears to exclude the possibility of mesothelioma; however, focal Leu M1 reactivity may indeed be seen in mesothelioma. Although CA-125 is a sensitive marker for serous carcinoma, it is not effective in distinguishing it from mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473660     DOI: 10.1097/00000478-198908000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  Differential expression of jackfruit-lectin-specific glycoconjugates in metastatic adenocarcinoma and reactive mesothelial cells-a diagnostic aid in effusion cytology.

Authors:  K Sujathan; S Kannan; P Remani; K R Pillai; B Chandralekha; N S Amma; M K Nair
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.

Authors:  L T Vlasveld; B G Taal; B B Kroon; M P Gallee; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Peritoneal carcinomatosis of gastrointestinal tumors: where are we now?

Authors:  Cem Terzi; Naciye Cigdem Arslan; Aras Emre Canda
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 4.  Well-differentiated papillary mesothelioma of the peritoneum: a borderline mesothelioma. Report of two cases and review of literature.

Authors:  K F Bürrig; P Pfitzer; W Hort
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 5.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

6.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  The differential diagnosis of primary peritoneal papillary tumors.

Authors:  G Gitsch; U Tabery; W Feigl; G Breitenecker
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

8.  Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details.

Authors:  Koray Topgül; Mehmet Bilge Çetinkaya; N Çiğdem Arslan; Mustafa Kemal Gül; Murat Çan; Mahmut Fikret Gürsel; Dilek Erdem; Zafer Malazgirt
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01

Review 9.  Peritoneal carcinomatosis.

Authors:  Federico Coccolini; Federico Gheza; Marco Lotti; Salvatore Virzì; Domenico Iusco; Claudio Ghermandi; Rita Melotti; Gianluca Baiocchi; Stefano Maria Giulini; Luca Ansaloni; Fausto Catena
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

10.  Significance of a galactose specific plant lectin for the differential diagnosis of adenocarcinoma cells in effusion.

Authors:  K Sujathan; K Jayasree; P Remani
Journal:  J Cytol       Date:  2009-10       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.